Drugs News and Research RSS Feed - Drugs News and Research

Catheter ablation improves quality of life for adults with atrial fibrillation

Catheter ablation improves quality of life for adults with atrial fibrillation

Adults who undergo a minimally invasive technique to treat atrial fibrillation are significantly less likely to die from a heart attack or heart failure, according to a long-term study by the University of Michigan Frankel Cardiovascular Center. [More]
First Edition: July 30, 2014

First Edition: July 30, 2014

Today's headlines include a range of health policy headines, including news from Capitol Hill on the Senate confirmation of Robert McDonald to head the VA. [More]
Study: Socialization emerges as relative strength in boys with fragile X

Study: Socialization emerges as relative strength in boys with fragile X

Standard scores measuring "adaptive behavior" in boys with fragile X syndrome tend to decline during childhood and adolescence, the largest longitudinal study of the inherited disorder to date has found. [More]
Adolescents get better care when health care visit is confidential, say researchers

Adolescents get better care when health care visit is confidential, say researchers

Teens who have the option to privately and confidentially discuss health concerns with their doctor are more likely to talk about reproductive health, mental health, issues at school, and some self-care topics than they would be in discussions where a parent is present, finds a new study in the Journal of Adolescent Health. [More]
FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME). [More]
Cloud Pharmaceuticals awarded Phase I grant from NSF SBIR program

Cloud Pharmaceuticals awarded Phase I grant from NSF SBIR program

Cloud Pharmaceuticals, Inc., a therapeutics company focused on cloud-based drug design and development, announced today that it has been awarded a Phase I grant from the National Science Foundation Small Business Innovation Research program. [More]
FDA approves use of Imbruvica to treat patients with chronic lymphocytic leukemia

FDA approves use of Imbruvica to treat patients with chronic lymphocytic leukemia

The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL. Imbruvica received a breakthrough therapy designation for this use. [More]
Kurbo program launched to tackle childhood obesity epidemic using mobile tools

Kurbo program launched to tackle childhood obesity epidemic using mobile tools

Kurbo Health today announced the launch of Kurbo, the first safe and effective program to tackle the childhood obesity epidemic using mobile tools. For the first time, children, teens and their parents have access to a safe, effective and proven mobile platform for losing weight. [More]
Viewpoints: GOP's 'political sideshow;' Boehner says House must defend the constitution; Jonathan Gruber on center stage about subsidies

Viewpoints: GOP's 'political sideshow;' Boehner says House must defend the constitution; Jonathan Gruber on center stage about subsidies

This week, before the House leaves for its August recess, the GOP majority is expected to approve a lawsuit against Obama. [More]
Biochemists report advance in production of functional mirror-image proteins

Biochemists report advance in production of functional mirror-image proteins

University of Utah biochemists have reported an advance in the production of functional mirror-image proteins. [More]
Hardship exemptions allow some to continue to buy coverage on health law's marketplaces

Hardship exemptions allow some to continue to buy coverage on health law's marketplaces

Elsewhere, the San Jose Mercury News examines who can opt out of the health law's mandate to have insurance on religious grounds. [More]
Findings reveal new way to identify non-antibiotic drugs that could help curb bacterial infections

Findings reveal new way to identify non-antibiotic drugs that could help curb bacterial infections

About 100 drugs already approved by the U.S. Food and Drug Administration (FDA) for other purposes can also prevent the growth of certain bacterial pathogens inside human cells, including those that cause Legionnaires' disease, brucellosis, and Mediterranean spotted fever. [More]
Researchers one step closer to finding treatment for Alzheimer's, other forms of dementia

Researchers one step closer to finding treatment for Alzheimer's, other forms of dementia

There is no cure for Alzheimer's disease and other forms of dementia, but the research community is one step closer to finding treatment. [More]
Research points to new direction for potential therapies to treat mucoepidermoid carcinoma

Research points to new direction for potential therapies to treat mucoepidermoid carcinoma

Research conducted at the Florida campus of The Scripps Research Institute has discovered links between a set of genes known to promote tumor growth and mucoepidermoid carcinoma, an oral cancer that affects the salivary glands. The discovery could help physicians develop new treatments that target the cancer's underlying genetic causes. [More]
PLXNA4 gene may increase risk of developing Alzheimer's disease

PLXNA4 gene may increase risk of developing Alzheimer's disease

Researchers from Boston University School of Medicine report variants in a new gene, PLXNA4, which may increase the risk of developing Alzheimer's disease (AD). The discovery of this novel genetic association may lead to new drug treatment options that target PLXNA4 specifically. [More]

Psychemedics' Q2 revenue increases 12% to $7.7 million

Psychemedics Corporation today announced second quarter financial results for the period ended June 30, 2014. The Company also announced a quarterly dividend of $0.15 per share payable to shareholders of record as of August 7, 2014 to be paid on August 18, 2014. [More]
Cardioxyl reports positive results from CXL-1427 Phase I trial for treatment of ADHF

Cardioxyl reports positive results from CXL-1427 Phase I trial for treatment of ADHF

Cardioxyl Pharmaceuticals, Inc. announced today the positive results of a clinical trial demonstrating that CXL-1427, a novel potential treatment for acute decompensated heart failure (ADHF), was well tolerated in healthy volunteers. [More]
New study in recognition of World Hepatitis Day released on Life Sciences Connect

New study in recognition of World Hepatitis Day released on Life Sciences Connect

The Intellectual Property and Science business of Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today released a new study in recognition of World Hepatitis Day on Life Sciences Connect, a blog exploring the latest news and trends in Life Sciences and updates on the drug pipeline identifying multiple treatments in development that may serve as potential alternatives to Gilead's Sovaldi, currently priced in the United States at $84,000 for 12 weeks of treatment - $1000 per pill. [More]
Antifungal drug resistance evoked through RNAi-dependent epimutations

Antifungal drug resistance evoked through RNAi-dependent epimutations

Microorganisms like bacteria and fungi can evade treatment by acquiring mutations in the genes targeted by antibiotics or antifungal drugs. [More]
Adopting a comprehensive and integrative healing strategy for cancer

Adopting a comprehensive and integrative healing strategy for cancer

The cancer drugs, radiation therapy and cancer surgery available today help millions of people survive their cancer. [More]